INTELLIGENT BIO SOLUTIONS INC. Revenue from Contract with Customer, Excluding Assessed Tax
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $4.22 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-19.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-19
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.15M, a 35.78% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.06M, a 45.54% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $896.77K, a 47.62% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.11M, a 27.46% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2026 was $4.22M, a 38.09% increase from fiscal 2025.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $3.05M, a 1.90% decline from fiscal 2024.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $3.11M, a 147.58% increase from fiscal 2023.
- INTELLIGENT BIO SOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.26M, a 187.52% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $2.21M derived: sum of 2 quarters · filed 2026-08-19 | $3.10M derived: sum of 3 quarters · filed 2026-08-19 | $4.22M 10-K · filed 2026-08-19 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-13 | $1.96M derived: sum of 2 quarters · filed 2026-05-13 | $3.07M 10-Q · filed 2026-05-13 | $3.91M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $896.77K 10-Q · filed 2026-02-12 | $2.01M 10-Q · filed 2026-02-12 | $2.85M derived: sum of 3 quarters · filed 2026-08-19 | $3.58M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-12 | $1.96M derived: sum of 2 quarters · filed 2026-08-19 | $2.68M derived: sum of 3 quarters · filed 2026-08-19 | $3.29M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $843.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $1.57M derived: sum of 2 quarters · filed 2026-08-19 | $2.18M derived: sum of 3 quarters · filed 2026-08-19 | $3.05M 10-K · filed 2026-08-19 |
| 2025-03-31 | $728.87K 10-Q · filed 2026-05-13 | $1.34M derived: sum of 2 quarters · filed 2026-05-13 | $2.21M 10-Q · filed 2026-05-13 | $2.94M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $607.49K 10-Q · filed 2026-02-12 | $1.48M 10-Q · filed 2026-02-12 | $2.21M derived: sum of 3 quarters · filed 2026-02-12 | $3.03M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $872.29K 10-Q · filed 2025-11-12 | $1.60M derived: sum of 2 quarters · filed 2025-11-12 | $2.42M derived: sum of 3 quarters · filed 2025-11-12 | $3.19M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $727.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $1.55M derived: sum of 2 quarters · filed 2025-08-15 | $2.32M derived: sum of 3 quarters · filed 2025-08-15 | $3.11M 10-K · filed 2025-08-15 |
| 2024-03-31 | $823.80K 10-Q · filed 2025-05-13 | $1.59M derived: sum of 2 quarters · filed 2025-05-13 | $2.38M 10-Q · filed 2025-05-13 | $2.83M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $764.06K 10-Q · filed 2025-02-13 | $1.56M 10-Q · filed 2025-02-13 | $2.00M derived: sum of 3 quarters · filed 2025-02-13 | $2.46M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $796.09K 10-Q · filed 2024-11-07 | $1.24M derived: sum of 2 quarters · filed 2024-11-07 | $1.70M derived: sum of 3 quarters · filed 2024-11-07 | $2.05M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $443.13K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $900.19K derived: sum of 2 quarters · filed 2024-09-18 | $1.26M derived: sum of 3 quarters · filed 2024-09-18 | $1.26M 10-K · filed 2024-09-18 |
| 2023-03-31 | $457.06K 10-Q · filed 2024-05-08 | $813.74K derived: sum of 2 quarters · filed 2024-05-08 | $813.74K 10-Q · filed 2024-05-08 | $1.19M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $356.68K 10-Q · filed 2024-02-09 | $356.68K 10-Q · filed 2024-02-09 | $734.85K derived: sum of 3 quarters · filed 2024-02-09 | $927.35K derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-09-30 | $311.32K 10-Q · filed 2022-11-14 | $378.18K derived: sum of 2 quarters · filed 2022-11-14 | $570.67K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2022-06-30 | $66.86K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-22 | $259.36K derived: sum of 2 quarters · filed 2022-09-22 | $437.15K 10-K · filed 2022-09-22 | |
| 2022-03-31 | $192.50K 10-Q · filed 2022-05-16 | $370.29K 10-Q · filed 2022-05-16 | ||
| 2021-06-30 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-22 | $1.64M derived: sum of 2 quarters · filed 2022-09-22 | $1.98M 10-K · filed 2022-09-22 | |
| 2021-03-31 | $34.29K 10-Q · filed 2022-05-16 | $372.75K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |